Results 131 to 140 of about 64,978 (265)

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

Infectious Complications in Patients with B-Cell Non-Hodgkin Lymphoma Treated with Bispecific Antibodies. [PDF]

Cancers (Basel)
Szymczyk A, Drozd-Sokołowska J, Hus I.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Prognostic implication of serum levels of IL-6 and IL-10 in children and adolescents with aggressive mature B-cell non-Hodgkin lymphoma. [PDF]

BMC Cancer
Zeng C, Wei Z, Huang J, Zhu J, Sun F, Wang J, Lu S, Zhang Y, Sun X, Zhen Z.   +9 more
europepmc   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

British Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena, Muhammad Shahzeb Khan, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Markus S. Anker   +5 more
wiley   +1 more source

Targeting CD30L in B-cell non-Hodgkin lymphoma: novel peptide conjugates and their therapeutic potential. [PDF]

Mol Cancer
Shi C, Lan T, Gao Y, Liang Z, Zhang Y, Tu Y, Liu H, Tu Z.   +7 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma. [PDF]

J Pers Med
Sun L, Romancik JT.
europepmc   +1 more source

Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
Zachary Hunzeker, Francisco Javier de la Rosa, Andrey Tyshevich, Darya Shavronskaya, Julia Alesse, Noel English, Lizzie Sheehan, Nikita Syzrantsev, Alexander Nesmelov, Hans‐Guido Wendel, Paolo Strati   +10 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source